SCHEDULE: Woodline Partners Reports 2.5% Stake in Tango Therapeutics

Woodline Partners LP has disclosed a beneficial ownership of 4,000,567 shares, representing 2.5% of the outstanding common stock of Tango Therapeutics, Inc.

Summary

• Woodline Partners LP, an investment adviser, has filed a Schedule 13G, indicating it beneficially owns 4,000,567 shares of Tango Therapeutics, Inc. common stock.
• This ownership stake represents 2.5% of the company's outstanding common stock.
• The shares were acquired and are held in the ordinary course of business, not for the purpose of influencing control of the issuer.
• The filing is an amendment (Amendment No. 3) to a previous filing, with the event date requiring this statement being June 30, 2026.

Sentiment

Score: 3

Explanation: StockSavvy.ai views this filing as neutral to slightly negative, primarily due to the passive nature of the disclosure and the indication of a significant ownership stake without immediate strategic commentary.

Positives

• Woodline Partners LP, a registered investment adviser, has taken a notable position in Tango Therapeutics, Inc.
• The ownership stake of 2.5% is significant enough to warrant disclosure, suggesting a level of confidence or strategic interest.

Negatives

• The filing is a Schedule 13G, which is typically a passive filing by institutional investors who own more than 5% of a class of securities, indicating no intent to influence control.
• The disclosure does not provide specific reasons for the investment or any forward-looking strategic plans related to Tango Therapeutics.

Risks

• The filing does not explicitly detail risks associated with the investment itself, but the nature of a Schedule 13G filing implies the investor is not actively seeking to control or influence the company, which could be a risk if the company's performance falters and the investor decides to divest.
• The calculation of the percentage of class is based on outstanding shares including those offered in a recent prospectus and shares reported in a prior 10-Q, which could be subject to change with future offerings or reporting.

Future Outlook

The filing does not contain any forward-looking statements or guidance from Woodline Partners LP regarding Tango Therapeutics, Inc.

Management Comments

• The filing of this statement should not be construed as an admission that any of the foregoing persons or the Reporting Person is, for the purposes of Section 13 of the Securities Exchange Act of 1934, the beneficial owner of the shares of Common Stock reported herein.
• By: Erin Mullen, General Counsel & Chief Compliance Officer: 'I certify that the information set forth in this statement is true, complete and correct.'

Industry Context

StockSavvy.ai notes that this Schedule 13G filing by Woodline Partners LP, an investment adviser, indicates a passive investment in Tango Therapeutics, Inc. This is common in the biotechnology sector where institutional investors often take significant stakes in companies with promising pipelines, but without immediate intentions to control or influence management.

Stakeholder Impact

• Shareholders: The disclosure of a significant institutional investor like Woodline Partners LP may be viewed positively, potentially indicating confidence in the company's prospects. However, the passive nature of the filing means no immediate strategic shift is implied.
• Management: The filing does not suggest any immediate intent to influence management decisions, allowing current leadership to continue with their existing strategies.
• Potential Investors: The presence of Woodline Partners LP as a shareholder could attract other investors, but the lack of detailed strategy may temper immediate enthusiasm.

Next Steps

• Monitor future filings from Woodline Partners LP for any changes in ownership or strategic commentary.
• Observe Tango Therapeutics, Inc.'s performance and strategic announcements for potential correlation with Woodline Partners' investment.

Key Dates

Keywords

Tango Therapeutics, Woodline Partners LP, Schedule 13G, Beneficial Ownership, Investment Adviser, Common Stock, SEC Filing, Biotechnology